Introduction/Objective: Tuberculosis (TB) is an infectious disease caused by bacteria belonging to the Mycobacterium tuberculosis complex. It is transmitted through the air and can affect various human tissues, particularly the lungs. TB remains a major global health challenge and a significant public health problem because of its airborne transmission and socioeconomic impact on affected individuals. The objective of this study is to evaluate the implementation of the World Health Organization (WHO) guidelines for the management of drug-susceptible tuberculosis among adults in North American countries. Methods: This study analyzes standardized treatment regimens in Mexico, the United States, and Canada. It assesses the clinical application of antituberculosis drugs, including isoniazid, pyrazinamide, ethambutol, rifampicin, rifapentine, rifabutin, moxifloxacin, and levofloxacin, within their respective national healthcare systems. This research analyzes standardized treatment schemes in Mexico, the United States, and Canada. Results: While treatment protocols in Canada, Mexico, and the United States are consistent with the recommendations of WHO guidelines, specific treatment regimens are tailored to the demographic and clinical needs of each population. Thus, these adaptations may influence healthcare coverage and the overall clinical effectiveness of the interventions. Discussion: Differences in how countries implement their TB control strategies may be associated with several epidemiological patterns. The significance of these findings lies in the possibility that variations in resource availability and differences in the adaptation of clinical guidelines may contribute to the observed epidemiological factors of TB across the region. Conclusion: North American countries have adapted their TB treatment regimens over time in accordance with international standards. However, differences in implementation and resource availability may be associated with variations in TB incidence and mortality rates. Strengthening universal access to TB prevention, diagnosis, and treatment remains essential to reduce catastrophic health expenditures and control the TB epidemic.